Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarization

• Published in: Proceedings of the National Academy of Sciences - PNAS 2016-02, Vol.113 (5), p.1339-1344
• Main Authors: Kuipers, Hedwich F., Rieck, Mary, Gurevich, Irina, Nagy, Nadine, Butte, Manish J., Negrin, Robert S., Wight, Thomas N., Steinman, Lawrence, Bollyky, Paul L.
• Format: Article
• Language: English
• Subjects: Animals; Biological Sciences; Brain; Cell Polarity; Experiments; Hyaluronic Acid - antagonists & inhibitors; Hyaluronic Acid - biosynthesis; Hymecromone - pharmacology; Lymphocyte Activation; Lymphocytes; Matrix; Mice; Mice, Inbred C57BL; Pathogenesis; Polarization; Rodents; T-Lymphocytes - immunology
• ISSN: 0027-8424; 1091-6490
• DOI: 10.1073/pnas.1525086113

The extracellular matrix polysaccharide hyaluronan (HA) accumulates at sites of autoimmune inflammation, including white matter lesions in multiple sclerosis (MS), but its functional importance in pathogenesis is unclear. We have evaluated the impact of 4-methylumbelliferone (4-MU), an oral inhibitor of HA synthesis, on disease progression in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Treatment with 4-MU decreases the incidence of EAE, delays its onset, and reduces the severity of established disease. 4-MU inhibits the activation of autoreactive T cells and prevents their polarization toward a Th1 phenotype. Instead, 4-MU promotes polarization toward a Th2 phenotpye and induction of Foxp3⁺ regulatory T cells. Further, 4-MU hastens trafficking of T cells through secondary lymphoid organs, impairs the infiltration of T cells into the CNS parenchyma, and limits astrogliosis. Together, these data suggest that HA synthesis is necessary for disease progression in EAE and that treatment with 4-MU may be a potential therapeutic strategy in CNS autoimmunity. Considering that 4-MU is already a therapeutic, called hymecromone, that is approved to treat biliary spasm in humans, we propose that it could be repurposed to treat MS.